Open labelled, single arm, interventional study of dutasteride injection for androgenetic alopecia.
Phase 4
- Conditions
- Health Condition 1: L649- Androgenic alopecia, unspecified
- Registration Number
- CTRI/2024/03/064041
- Lead Sponsor
- CUTIS Academy of Cutaneous Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age abve 18 years – 55 years.
Newly diagnosed cases of androgenetic alopecia.
Naive cases of AGA and non-responders of topical minoxidil.
Baseline serum DHT level within normal range.
Females of child-bearing potential agree to use a reliable method of birth control or remain absent during the study
Post menopausal females.
All other treatments for androgenetic alopecia are prohibited during the course of the study
Exclusion Criteria
Patients using the following medications: inhibitors of CYP3A4 (verapamil) or drugs with antiandrogen effect (finasteride) in the last six months.
Patients suffering from ejaculatory or erectile dysfunction.
Pregnant & breast-feeding females
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The efficacy and safety of Dutasteride mesotherapy in androgenic alopeciaTimepoint: After 4 months
- Secondary Outcome Measures
Name Time Method Trichoscopic assessment will be done at every visit, (Base line, Week 4, week 8, week 12 & week 16) <br/ ><br>Assessment of hair regrowth will be performed at every visit. <br/ ><br>Standardized digital photography will be performed at every visit. <br/ ><br> <br/ ><br>Timepoint: After 4 months